San Francisco, CA, United States of America

Luke Evnin

This inventor holds 24 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Harpoon Therapeutics, Inc., Werewolf Therapeutics, Inc., Amphivena Therapeutics, Inc.. Active years: 2015-2026.

USPTO Granted Patents = 24 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 6.1

ph-index = 8

Forward Citations = 180(Granted Patents)

Company Filing History:

9 out of 25

Harpoon Therapeutics, Inc.

patents

8 out of 12

Werewolf Therapeutics, Inc.

patents

4 out of 4

Amphivena Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

patents

6. 1 out of 834,350

Other

patents

Years Active: 2015-2026

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528859 - SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN (2026-01-20),

2. 12275769 - Activatable interleukin 12 polypeptides and methods of use thereof (2025-04-14),

3. 12128102 - Constrained conditionally activated binding proteins (2024-10-29),

4. 12084518 - Trispecific binding proteins and methods of use (2024-09-10),

5. 11981716 - Activatable interleukin-2 polypeptides and methods of use thereof (2024-05-14),

6. 11753469 - Methods of using bispecific CD33 and CD3 binding proteins (2023-09-12),

7. 11739132 - Separation moieties and methods of use thereof (2023-08-29),

8. 11623958 - Single chain variable fragment CD3 binding proteins (2023-04-11),

9. 11535658 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-12-27),

10. 11453716 - Single domain serum albumin binding protein (2022-09-27),

11. 11453710 - Activatable interleukin 12 polypeptides and methods of use thereof (2022-09-27),

12. 11352403 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-06-07),

13. 10954311 - Trispecific binding proteins and methods of use (2021-03-23),

14. 10738118 - Methods of using bispecific CD33 and CD3 binding proteins (2020-08-11),

15. 10696724 - Activatable interleukin-2 polypeptides (2020-06-30),

Title: The Innovative Journey of Luke Evnin

Introduction: Luke Evnin, a renowned inventor based in San Francisco, CA, has made significant contributions to the field of technology and innovation.

Latest Patents: Luke Evnin holds several patents in the areas of biotechnology, pharmaceuticals, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights: With a background in biochemistry and a Ph.D. from Stanford University, Luke Evnin co-founded MPM Capital, a venture capital firm specializing in life sciences. His entrepreneurial spirit and vision have led to the successful funding and development of numerous groundbreaking projects in the healthcare industry.

Collaborations: Throughout his career, Luke Evnin has collaborated with leading researchers, scientists, and entrepreneurs to drive innovation and bring cutting-edge technologies to the market. His ability to foster partnerships and build interdisciplinary teams has been instrumental in the success of many projects.

Conclusion: Luke Evnin's passion for innovation, coupled with his scientific acumen and business acuity, has established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators and entrepreneurs.